Dengue fever is caused by the mosquito-borne dengue virus (DENV), which is endemic in more than 100 countries. Annually, there are approximately 390 million dengue cases, with a small subset manifesting into severe illnesses, such as dengue haemorrhagic fever or dengue shock syndrome. Current treatment options for dengue infections remain supportive management due to the lack of an effective vaccine and clinically approved antiviral. Although the CYD-TDV (Dengvaxia®) vaccine with an overall vaccine efficacy of 60 % has been licensed for clinical use since 2015, it poses an elevated risk of severe dengue infections especially in dengue-naïve children below 9 years of age. The newly approved Qdenga vaccine was able to achieve an overall vaccine efficacy of 80 % after 12 months, but it was not able to provide a protective effect against DENV-3 in dengue naïve individuals. The Butantan-DV vaccine candidate is still undergoing phase 3 clinical trials for safety and efficacy evaluations in humans. Apart from live-attenuated vaccines, various other vaccine types are also currently being studied in preclinical and clinical studies. This review discusses the current status of dengue vaccine development.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11741033 | PMC |
| http://dx.doi.org/10.1016/j.jvacx.2024.100604 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discover the status of invasive Aedes species and the challenges in dengue surveillance and control in Iran.
New Microbes New Infect
February 2025
Department of Vector Biology & Control of Diseases , School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Background And Aims: Dengue is a mosquito-borne viral disease that frequently causes seasonal outbreaks in Bangladesh, particularly during the monsoon months from June to September. Recent outbreaks have shown significant shifts in clinical manifestations, including changes in the timeframe and serotype mixing. This study focused on the clinical and hematological profiles of patients during the 2022 outbreak, which was notably severe.
View Article and Find Full Text PDFAPPLICATIONS OF MATHEMATICAL PROGRAMMING TO GENETIC BIOCONTROL.
SIAM J Appl Math
January 2024
Division of Epidemiology and Biostatistics, School of Public Health, University of California Berkeley, Berkeley, CA 94704 USA.
We review existing approaches to optimizing the deployment of genetic biocontrol technologies-tools used to prevent vector-borne diseases such as malaria and dengue-and formulate a mathematical program that enables the incorporation of crucial ecological and logistical details. The model is comprised of equality constraints grounded in discretized dynamic population equations, inequality constraints representative of operational limitations including resource restrictions, and an objective function that jointly minimizes the count of competent mosquito vectors and the number of transgenic organisms released to mitigate them over a specified time period. We explore how nonlinear programming (NLP) and mixed integer nonlinear programming (MINLP) can advance the state of the art in designing the operational implementation of three distinct transgenic public health interventions, two of which are presently in active use around the world.
View Article and Find Full Text PDFCurrent status of the development of dengue vaccines.
Vaccine X
January 2025
ALPS Global Holding Berhad, The ICON, East Wing Tower, No. 1, Jalan 1/68F, Off Jalan Tun Razak, Kuala Lumpur 50400, Malaysia.
Dengue fever is caused by the mosquito-borne dengue virus (DENV), which is endemic in more than 100 countries. Annually, there are approximately 390 million dengue cases, with a small subset manifesting into severe illnesses, such as dengue haemorrhagic fever or dengue shock syndrome. Current treatment options for dengue infections remain supportive management due to the lack of an effective vaccine and clinically approved antiviral.
View Article and Find Full Text PDFBackground: Dengue, chikungunya, and Zika are mosquito-borne diseases of major human concern. Differential diagnosis is complicated in children and adolescents by their overlapping clinical features (signs, symptoms, and complete blood count results). Few studies have directly compared the three diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!